(4-((1H-Pyrazol-1-yl)methyl)phenyl)boronic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-((1H-Pyrazol-1-yl)methyl)phenyl)boronic acid
• 英文别名: [4-(pyrazol-1-ylmethyl)phenyl]boronic acid
• 化学式: C₁₀H₁₁BN₂O₂
• 分子量: 202.021
• InChiKey: XIYRZIBHPJLCKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.39
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  58.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-磺酰胺-4-碘苯 、 (4-((1H-Pyrazol-1-yl)methyl)phenyl)boronic acid 在 palladium catalyst 作用下， 生成 4-[4-(Pyrazol-1-ylmethyl)phenyl]benzenesulfonamide
  参考文献：
  名称：

  Sulfonamide carbonic anhydrase inhibitors: Zinc coordination and tail effects influence inhibitory efficacy and selectivity for different isoforms

  摘要：

  The metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1) is effectively inhibited by primary sulfonamides which coordinate as anions to the zinc ion from its active site. Inhibition of CAs has pharmacologic applications in the treatment of many diseases, but many sulfonamides are promiscuous inhibitors of most isoforms known to date, leading to side effects of these drugs. In a series of 4-aryl-benzenesulfonamides with effective inhibitory action against human (h) isoforms hCA I, II, IX and XII and selectivity for some of them, we demonstrate by means of X-ray crystallographic studies of enzyme-inhibitor adducts, that the tail present on the benzenesulfonamide scaffold significantly contributes to the observed inhibition/selectivity profile. This study may bring additional information for the structure-based drug design of effective/isoform-selective zinc-binding CA inhibitors. (C) 2017 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2017.03.038

文献信息

• Heterobicyclic thiophene compounds and methods of use
  申请人：Blake F. James

  公开号：US20070197537A1

  公开（公告）日：2007-08-23

  Compounds of Formula I and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula I and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式I的化合物及其药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。本文揭示了使用公式I的化合物及其药学上可接受的盐，在哺乳动物细胞中进行体外、体内诊断、预防或治疗此类疾病或相关病理条件的方法。